Blocking iron uptake and metabolism has been emerging as a promising therapeutic strategy for the development of novel antimicrobial compounds. Like all mycobacteria, M. abscessus (Mab) has evolved several countermeasures to scavenge iron from host carrier proteins, including the production of siderophores, which play a crucial role in these processes. In this study, we solved, for the first time, the crystal structure of Mab-SaS, the first enzyme involved in the biosynthesis of siderophores. Moreover, we screened a small, focused library and identified a compound exhibiting a potent inhibitory effect against Mab-SaS (IC50 ≈ 2 μM). Its binding mode was investigated by means of Induced Fit Docking simulations, performed on the crystal structure presented herein. Furthermore, cytotoxicity data and pharmacokinetic predictions revealed the safety and drug-likeness of this class of compounds. Finally, the crystallographic data were used to optimize the model for future virtual screening campaigns. Taken together, the findings of our study pave the way for the identification of potent Mab-SaS inhibitors, based on both established and unexplored chemotypes.

Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus / M. Mori, M. Cocorullo, A. Tresoldi, G. Cazzaniga, A. Gelain, G. Stelitano, L.R. Chiarelli, M. Tomaiuolo, P. Delre, G.F. Mangiatordi, M. Garofalo, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 265:(2024 Feb 05), pp. 116073.1-116073.13. [10.1016/j.ejmech.2023.116073]

Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus

M. Mori
Primo
;
A. Tresoldi;G. Cazzaniga;A. Gelain;S. Villa
Penultimo
;
F. Meneghetti
Ultimo
2024

Abstract

Blocking iron uptake and metabolism has been emerging as a promising therapeutic strategy for the development of novel antimicrobial compounds. Like all mycobacteria, M. abscessus (Mab) has evolved several countermeasures to scavenge iron from host carrier proteins, including the production of siderophores, which play a crucial role in these processes. In this study, we solved, for the first time, the crystal structure of Mab-SaS, the first enzyme involved in the biosynthesis of siderophores. Moreover, we screened a small, focused library and identified a compound exhibiting a potent inhibitory effect against Mab-SaS (IC50 ≈ 2 μM). Its binding mode was investigated by means of Induced Fit Docking simulations, performed on the crystal structure presented herein. Furthermore, cytotoxicity data and pharmacokinetic predictions revealed the safety and drug-likeness of this class of compounds. Finally, the crystallographic data were used to optimize the model for future virtual screening campaigns. Taken together, the findings of our study pave the way for the identification of potent Mab-SaS inhibitors, based on both established and unexplored chemotypes.
Chorismate; Crystal structure; Cystic fibrosis; Inhibition; Mycobacterium abscessus; Non-tuberculous mycobacteria; Salicylate synthase; Siderophores;
Settore CHIM/08 - Chimica Farmaceutica
5-feb-2024
20-dic-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
EJMC 2024 Villa et al..pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 5.28 MB
Formato Adobe PDF
5.28 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1023181
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact